

# INPLASY PROTOCOL

To cite: Liang et al. Efficacy and safety evaluation of radiotherapy options after lumpectomy for early-stage breast cancer: a systematic review and network meta-analysis of randomized clinical trials. Inplasy protocol 202180093. doi: 10.37766/inplasy2021.8.0093

Received: 24 August 2021

Published: 24 August 2021

**Corresponding author:**  
Liang-Xi Xie

lxxie@xah.xmu.edu.cn

**Author Affiliation:**  
Xiang'an Hospital of Xiamen University

**Support:** None.

**Review Stage at time of this submission:** Preliminary searches.

**Conflicts of interest:**  
None declared.

## INTRODUCTION

**Review question / Objective:** P: early-stage breast cancer; I: radiotherapy options after lumpectomy; C: whole-breast irradiation (WBI); O: the primary endpoint is the rate of

## Efficacy and safety evaluation of radiotherapy options after lumpectomy for early-stage breast cancer: a systematic review and network meta-analysis of randomized clinical trials

Liang, YQ<sup>1</sup>; Feng, SQ<sup>2</sup>; Xie, WJ<sup>3</sup>; Xie, LX<sup>4</sup>.

**Review question / Objective:** P: early-stage breast cancer; I: radiotherapy options after lumpectomy; C: whole-breast irradiation (WBI); O: the primary endpoint is the rate of ipsilateral breast tumor recurrence. Secondary endpoints are overall survival, disease-free survival, distant metastasis survival, acute toxicity, lateral mortality, cosmetic outcome. S: randomized clinical trials.

**Condition being studied:** The traditional radiotherapy after lumpectomy for early-stage breast cancer is WBI. Nowadays, ASTRO and ESTRO guidelines recommend using accelerated partial breast irradiation (APBI) instead of WBI for selected early-stage breast cancer. Options of APBI mainly include external beam radiation therapy, brachytherapy and intraoperative radiotherapy that has recently reported its long-term results. To evaluate the efficacy and safety evaluation of radiotherapy options after lumpectomy for early-stage breast cancer. We are going to conduct a systematic review and network meta-analysis of randomized clinical trials.

**INPLASY registration number:** This protocol was registered with the International Platform of Registered Systematic Review and Meta-Analysis Protocols (INPLASY) on 24 August 2021 and was last updated on 24 August 2021 (registration number INPLASY202180093).

ipsilateral breast tumor recurrence. Secondary endpoints are overall survival, disease-free survival, distant metastasis survival, acute toxicity, lateral mortality, cosmetic outcome. S: randomized clinical trials.

**Condition being studied:** The traditional radiotherapy after lumpectomy for early-stage breast cancer is WBI. Nowadays, ASTRO and ESTRO guidelines recommend using accelerated partial breast irradiation (APBI) instead of WBI for selected early-stage breast cancer. Options of APBI mainly include external beam radiation therapy, brachytherapy and intraoperative radiotherapy that has recently reported its long-term results. To evaluate the efficacy and safety evaluation of radiotherapy options after lumpectomy for early-stage breast cancer. We are going to conduct a systematic review and network meta-analysis of randomized clinical trials.

## METHODS

**Participant or population:** (1) early-stage breast cancer; (2) after breast-conserving surgery; (3) receiving breast radiotherapy.

**Intervention:** The group receiving accelerated partial breast radiotherapy.

**Comparator:** The group receiving whole breast radiotherapy.

**Study designs to be included:** Randomized controlled trials.

**Eligibility criteria:** (1) early-stage breast cancer; (2) breast-conserving surgery; (3) breast radiotherapy; (4) two independent comparison groups; (5) at least one endpoint was reported; (6) randomized controlled trials (RCTs); (7) language restrictions in English; (8) the sample size of the study was more than 50 cases.

**Information sources:** A systematical research will be performed of PubMed, EMBASE, WOS and Medline, and the Cochrane Library.

**Main outcome(s):** The primary endpoint is the rate of ipsilateral breast tumor recurrence.

**Additional outcome(s):** Secondary endpoints are overall survival, disease-free survival, distant metastasis survival, acute

toxicity, lateral mortality, cosmetic outcome.

**Quality assessment / Risk of bias analysis:** The quality will be assessed as the Grading of Recommendations Assessment, Development and Evaluation (GRADE) Working Group. Risk of bias will be assessed the Cochrane Collaboration tool.

**Strategy of data synthesis:** Using the Cochrane Q test and the I<sup>2</sup> statistics to evaluate the heterogeneity between studies. If heterogeneity is present (P50%), the statistical pooling of effect measures is based on the random-effect model. Otherwise, a fixed-effect model is employ. Forest plots with heterogeneity estimates will be generated.

**Subgroup analysis:** Subgroup analysis will be performed if possible.

**Sensitivity analysis:** The sensitivity analysis will be conducted by omitting one study in each turn.

**Language:** English.

**Country(ies) involved:** China.

**Keywords:** Breast cancer, Accelerated partial breast irradiation, Whole-breast irradiation, Network Meta-analysis.

### Contributions of each author:

Author 1 - Yu-Qin Liang.

Email: yqliang@xmu.edu.cn

Author 2 - Sen-Quan Feng.

Email: s.feng@umcg.nl

Author 3 - Wen-Jia Xie.

Email: xwj7203@163.com

Author 4 - Liang-Xi Xie.

Email: lxxie@xah.xmu.edu.cn